A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine preven...

por Ashina, Messoud, Doležil, David, Bonner, Jo H, Zhou, Lifen, Klatt, Jan, Picard, Hernan, Mikol, Daniel D
Publicado 2020

Remote electrical neuromodulation (REN) in the acute treatment of migraine: a comparison with usual care and acute migraine medications

por Rapoport, Alan M., Bonner, Jo H., Lin, Tamar, Harris, Dagan, Gruper, Yaron, Ironi, Alon, Cowan, Robert P.
Publicado 2019

The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response

por Broessner, Gregor, Reuter, Uwe, Bonner, Jo H., Dodick, David W., Hallström, Yngve, Picard, Hernan, Zhang, Feng, Lenz, Robert A., Klatt, Jan, Mikol, Daniel D.
Publicado 2020

Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials

por Tepper, Stewart J, Ashina, Messoud, Reuter, Uwe, Hallström, Yngve, Broessner, Gregor, Bonner, Jo H, Picard, Hernan, Cheng, Sunfa, Chou, Denise E, Zhang, Feng, Klatt, Jan, Mikol, Daniel D
Publicado 2021

One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study

por Goadsby, Peter J., Reuter, Uwe, Hallström, Yngve, Broessner, Gregor, Bonner, Jo H., Zhang, Feng, Wright, Ian K., Chou, Denise E., Klatt, Jan, Picard, Hernan, Lenz, Robert A., Mikol, Daniel D.
Publicado 2020